BioSpace News Archive

Today, Hoth Therapeutics, Inc. , announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.

Senseonics Holdings, Inc. today announced further presentation of PROMISE Study data evaluating the next generation Eversense CGM System at the American Diabetes Association Virtual 81st Annual Scientific Sessions.

Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) today announced that they have entered into a strategic partnership for the exclusive commercialization of Bioeq’s FYB201, a biosimilar candidate to Lucentis ®.

Dyadic announced today findings from the Zoonotic Anticipation and Preparedness Initiative (ZAPI) project which has been published in VACCINES, a leading peer-reviewed scientific journal.

Shoreline Biosciences, Inc. today announced the appointment of Mohammad El-Kalay , Ph.D., as Senior VP and Head of CMC

Aruvant Sciences today announced the appointment of Stanley J. Musial as chief financial officer (CFO) effective immediately.

Captivate Bio, a scientific cell culture solutions provider, today announced it has signed an exclusive distribution agreement with PL BioScience GmbH to bring its portfolio of human platelet lysate to markets across North America.

LivaNova PLC will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m. London time (8 a.m. Eastern Daylight Time).

A new study by Pendulum Therapeutics was presented at the American Diabetes Association’s 81st Scientific Sessions, the preeminent global conference for diabetes clinicians, researchers, and professionals where cutting-edge science and advances in diabetes research, prevention, and care are discussed.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association (ADA) 81st Scientific Session.